companydata.dkcompanydata.dk

NOVO NORDISK PHARMACEUTICALS A/S: Financial statements 2019

CVR: 24257924

Source: annual report 2019, Danish Business Authority

01/01/2019 – 31/12/2019

NOVO NORDISK PHARMACEUTICALS A/S (CVR 24257924) has filed annual accounts for 2019. In 2019, the company reported a net result of DKK 3,722,000 compared with DKK -1,984,000 the year before. Equity in the 2019 report amounted to DKK 15,569,000. The solvency ratio was 99.8%.

Profit/Loss
DKK 3,722,000
Equity
DKK 15,569,000
Total Assets
DKK 15,602,000

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2019--3.7M15.6M-
2018---2M11.8M-
2017---2.3M13.8M-
2016--1.7M16.1M-
2015--1.9M14.4M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2019

NOVO NORDISK PHARMACEUTICALS A/S: The 2018 annual report is outMay 27, 2019

NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2018. The net result was DKK -1,984,000.

About NOVO NORDISK PHARMACEUTICALS A/S

NOVO NORDISK PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1974. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named NOVO FARMAKA A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -53,000 and a net result of DKK 2,074,000 compared with DKK 6,918,000 the year before. Equity in the 2025 report amounted to DKK 12,325,000.

Source: annual report 2025, Danish Business Authority